Клиническая онкогематология

Клиническая онкогематология

Фундаментальные исследования и клиническая практика

Menu

  • Home
  • About
    • Aims and Scope
    • Editorial board
    • Indexing and Abstracting
    • Peer Review
    • Publishing Ethics and Malpractice Statement
    • Open Access Policy and Publication Fee
  • Archive
    • 2023
      • № 1/2023
    • 2022
      • № 1/2022
      • № 2/2022
      • № 3/2022
      • № 4/2022
    • 2021
      • № 1/2021
      • № 2/2021
      • № 3/2021
      • № 4/2021
    • 2020
      • Issue 1/2020
      • Issue 2/2020
      • Issue 3/2020
      • Issue 4/2020
    • 2019
      • №1/2019
      • № 2/2019
      • № 3/2019
      • № 4/2019
    • 2018
      • №1/2018
      • №2/2018
      • №3/2018
      • №4/2018
    • 2017
      • №1/2017
      • №2/2017
      • №3/2017
      • №4/2017
    • 2016
      • №1/2016
      • №2/2016
      • №3/2016
      • №4/2016
    • 2015
      • №1/2015
      • №2/2015
      • №3/2015
      • №4/2015
    • 2014
      • № 1/2014
      • №2/2014
      • №3/2014
      • №4/2014
    • 2013
      • №1/2013
      • №2/2013
      • №3/2013
      • №4/2013
  • Submission
    • Submit manuscript

New Treatment Options for Diffuse Large B-Cell Lymphoma

AUTOIMMUNE THROMBOCYTOPENIA

Matthew J. Matasar, MD

Medical Oncologist

Regional Care Network Medical Site Director, MSK Bergen

Memorial Sloan Kettering Cancer Center, New York, USA

The interview was conducted by Prof. E.A. Osmanov, MD, PhD.


Read in PDF

  • ← Breakthrough Hemolysis as a Challenging Issue in Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria (Resolution of Expert Panel)
  • The Use of Checkpoint Inhibitors in Classical Hodgkin’s Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center’s Experience) →

Languages

  • ru 
  • en 
  • Supportive Therapy in Multiple Myeloma: Practical Recommendations
  • Primary Immune Thrombocytopenia and Thrombopoietin Receptor Agonists: Feasibilities of Treatment Discontinuation upon Achieving Stable Complete Platelet Response
  • Cardiovascular Complications of the Immunotherapy of Hematological Malignancies: A Literature Review
  • An Optimal Multi-Locus HLA-Typing in Potential Donors of Allogeneic Hematopoietic Stem Cells
  • BAALC-Expressing Leukemia Hematopoietic Stem Cells and Their Place in the Study of CBF-Positive Acute Myeloid Leukemias in Children and Adults

Notifications